PRRC1

Across TCGA pan-cancer cohorts, PRRC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRRC1 data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRRC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRRC1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where PRRC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.494	0.324	.003	33	view →
CCRCC	OS	Median	All	0.629	1.000	.002	22	view →
UCEC	DFS	Median	All	0.964	0.848	.006	20	view →
LSCC	DFS	Tertile	II,III,IV	0.422	0.851	.003	20	view →
LUAD	DFS	Quartile	All	0.366	0.672	.024	4	view →
GBM	DFS	Tertile	All	0.643	0.858	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRRC1–PDAC (DFS)

Open the PDAC breakdown →